Immuron Limited is a biopharmaceutical company focused on developing and commercializing polyclonal antibody-based therapeutics and consumer health products. The company operates through research and development activities alongside commercialization of hyper-immune products. Its commercial portfolio includes Travelan, an over-the-counter product designed to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders, as well as Protectyn, a digestive health and liver support dietary supplement.
The company's pipeline includes multiple clinical-stage programs targeting infectious diseases and gastrointestinal disorders. Travelan (IMM-124E) is in Phase II clinical trials for travelers' diarrhea prevention, while IMM-529 is in Phase II development for recurring clostridium difficile infection. IMM-986 remains in preclinical development. Immuron has established research collaborations with the US Naval Medical Research Command and the Walter Reed Army Institute of Research to develop therapeutics targeting Campylobacter, enterotoxigenic Escherichia coli, and Shigella infections.
Immuron operates as a small-scale organization with seven full-time employees and is headquartered in Carlton, Victoria, Australia. The company maintains a Nasdaq listing and has geographic reach across Australia, the United States, and Canada. The company was incorporated in Australia in 1994 and operates its technology platform alongside product development and commercialization activities.
No 10-K filings found.